For the Inventor, By the Inventor

Enter assignee name

Brussels, Belgium

Ucb S.a.

USPTO Granted Patents = 119

% Expired Patents = 34.5

CIPO Patents = 2

EPO Patents = 2

Trademarks = 2

Forward Citations = 1,482

Loading Chart...

Loading Chart...

225 inventors (with patents filed for the assignee):

Daniel Maetens (15 out of 21 patents)

Jean-Marie Loutz (15 out of 15 patents)

Michel Deleers (13 out of 18 patents)

4. Luc Moens (12 out of 23 patents)

5. Jean Gobert (12 out of 18 patents)

6. Eric Cossement (11 out of 17 patents)

7. Philippe Michel (10 out of 18 patents)

8. Xiong Cai (9 out of 73 patents)

9. Domenico Fanara (8 out of 17 patents)

10. Anna Toy-Palmer (8 out of 8 patents)

11. Gurmit Grewal (8 out of 13 patents)

12. Guy Bodson (8 out of 12 patents)

13. Edmond Differding (7 out of 15 patents)

14. August Van Gysel (7 out of 7 patents)

15. Ernst Wulfert (6 out of 10 patents)

Core Competencies:

Pharmaceutical Compositions

Neurological Treatments

Anti-Inflammatory Agents

Asthma Treatments

Sclerostin-Binding Antibody

Bone Mineralization

GABA Compounds

Muscarinic Agonists

Epilepsy Treatments

Chemical Compounds

Diagnosis Methods

119 patents: Sort by Forward Citations

1. 8338621 - Process for the preparation of 2-oxo-1-pyrrolidine derivatives (2012-12-25),

2. 8003108 - Sclerostin epitopes (2011-08-23),

3. 7732614 - 2,6-quinolinyl derivatives, processes for preparing them and their uses (2010-06-08),

4. 7622278 - Compositions and methods for diagnosing or treating psoriasis (2009-11-24),

5. 7592429 - Sclerostin-binding antibody (2009-09-22),

6. 7585954 - Antibodies for diagnosing psoriasis (2009-09-08),

7. 7572899 - Compositions and methods for increasing bone mineralization (2009-08-11),

8. 7544675 - Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions (2009-06-09),

9. 7507542 - Method for regulating immune function using the FOXP3 protein (2009-03-24),

10. 7473697 - 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders (2009-01-06),

11. 7465549 - Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2) (2008-12-16),

12. 7381821 - Piperazine derivatives and their use as synthesis intermediates (2008-06-03),

13. 7361668 - Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors (2008-04-22),

14. 7358276 - 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2008-04-15),

15. 7244747 - Imidazole derivatives, processes for preparing them and their uses (2007-07-17),

UCB S.A. is a global biopharmaceutical company specializing in the research, development, and commercialization of innovative medicines and solutions for people living with severe diseases. With a focus on neurology and immunology, UCB aims to deliver solutions that improve the lives of patients worldwide. Through collaborations and partnerships, UCB strives to make a positive impact on healthcare globally.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

119 Patents

#12 in Brussels

#41 in Belgium

#6,680 in the World

Brussels, Belgium

Ucb S.a.

Forward Citations = 1,482

225 inventors:

Daniel Maetens (15 out of 21 patents)

Jean-Marie Loutz (15 out of 15 patents)

Michel Deleers (13 out of 18 patents)

4. Luc Moens (12 out of 23 patents)

5. Jean Gobert (12 out of 18 patents)

Please report any incorrect information to [email protected]

Loading…